Metrics to compare | POLB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPOLBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.9x | −1.3x | −0.5x | |
PEG Ratio | −0.32 | −0.01 | 0.00 | |
Price/Book | 3.9x | 1.8x | 2.6x | |
Price / LTM Sales | - | 1.3x | 3.1x | |
Upside (Analyst Target) | 297.5% | 205.3% | 54.0% | |
Fair Value Upside | Unlock | 10.4% | 6.5% | Unlock |
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, focused on acquiring, developing, and commercialising of medicines for unmet medical needs in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza and respiratory syncytial viruses. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.